189 related articles for article (PubMed ID: 23779108)
1. The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.
Mizanur RM; Frasca V; Swaminathan S; Bavari S; Webb R; Smith LA; Ahmed SA
J Biol Chem; 2013 Aug; 288(33):24223-33. PubMed ID: 23779108
[TBL] [Abstract][Full Text] [Related]
2. Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity.
Ahmed SA; Olson MA; Ludivico ML; Gilsdorf J; Smith LA
Protein J; 2008 Apr; 27(3):151-62. PubMed ID: 18213512
[TBL] [Abstract][Full Text] [Related]
3. Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.
Gul N; Smith LA; Ahmed SA
PLoS One; 2010 Sep; 5(9):e12872. PubMed ID: 20877571
[TBL] [Abstract][Full Text] [Related]
4. Differential endopeptidase activity of different forms of type A botulinum neurotoxin: A unique relationship between the size of the substrate and activity of the enzyme.
Ambrin G; Kumar R; Singh BR
Toxicon; 2018 Mar; 144():34-41. PubMed ID: 29309744
[TBL] [Abstract][Full Text] [Related]
5. Structural characterization of three novel hydroxamate-based zinc chelating inhibitors of the Clostridium botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility.
Thompson AA; Jiao GS; Kim S; Thai A; Cregar-Hernandez L; Margosiak SA; Johnson AT; Han GW; O'Malley S; Stevens RC
Biochemistry; 2011 May; 50(19):4019-28. PubMed ID: 21434688
[TBL] [Abstract][Full Text] [Related]
6. Botulinum neurotoxin detection and differentiation by mass spectrometry.
Barr JR; Moura H; Boyer AE; Woolfitt AR; Kalb SR; Pavlopoulos A; McWilliams LG; Schmidt JG; Martinez RA; Ashley DL
Emerg Infect Dis; 2005 Oct; 11(10):1578-83. PubMed ID: 16318699
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine phosphorylation of botulinum neurotoxin protease domains.
Toth S; Brueggmann EE; Oyler GA; Smith LA; Hines HB; Ahmed SA
Front Pharmacol; 2012; 3():102. PubMed ID: 22675300
[TBL] [Abstract][Full Text] [Related]
8. Unique substrate recognition by botulinum neurotoxins serotypes A and E.
Chen S; Barbieri JT
J Biol Chem; 2006 Apr; 281(16):10906-11. PubMed ID: 16478727
[TBL] [Abstract][Full Text] [Related]
9. Interactions of a potent cyclic peptide inhibitor with the light chain of botulinum neurotoxin A: Insights from X-ray crystallography.
Kumaran D; Adler M; Levit M; Krebs M; Sweeney R; Swaminathan S
Bioorg Med Chem; 2015 Nov; 23(22):7264-73. PubMed ID: 26522088
[TBL] [Abstract][Full Text] [Related]
10. Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin.
Shone CC; Roberts AK
Eur J Biochem; 1994 Oct; 225(1):263-70. PubMed ID: 7925446
[TBL] [Abstract][Full Text] [Related]
11. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction.
Rummel A; Mahrhold S; Bigalke H; Binz T
Mol Microbiol; 2004 Feb; 51(3):631-43. PubMed ID: 14731268
[TBL] [Abstract][Full Text] [Related]
12. Structure- and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A.
Kumaran D; Rawat R; Ludivico ML; Ahmed SA; Swaminathan S
J Biol Chem; 2008 Jul; 283(27):18883-91. PubMed ID: 18434312
[TBL] [Abstract][Full Text] [Related]
13. Structural characterisation of the catalytic domain of botulinum neurotoxin X - high activity and unique substrate specificity.
Masuyer G; Zhang S; Barkho S; Shen Y; Henriksson L; Košenina S; Dong M; Stenmark P
Sci Rep; 2018 Mar; 8(1):4518. PubMed ID: 29540745
[TBL] [Abstract][Full Text] [Related]
14. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate.
Zuniga JE; Schmidt JJ; Fenn T; Burnett JC; Araç D; Gussio R; Stafford RG; Badie SS; Bavari S; Brunger AT
Structure; 2008 Oct; 16(10):1588-97. PubMed ID: 18940613
[TBL] [Abstract][Full Text] [Related]
15. A cross-over inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of action.
Salzameda NT; Eubanks LM; Zakhari JS; Tsuchikama K; DeNunzio NJ; Allen KN; Hixon MS; Janda KD
Chem Commun (Camb); 2011 Feb; 47(6):1713-5. PubMed ID: 21203627
[TBL] [Abstract][Full Text] [Related]
16. Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25.
Chen S; Barbieri JT
J Biol Chem; 2011 Apr; 286(17):15067-72. PubMed ID: 21378164
[TBL] [Abstract][Full Text] [Related]
17. SNAP-25 substrate peptide (residues 180-183) binds to but bypasses cleavage by catalytically active Clostridium botulinum neurotoxin E.
Agarwal R; Swaminathan S
J Biol Chem; 2008 Sep; 283(38):25944-51. PubMed ID: 18658150
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of catalytic activities of botulinum neurotoxin light chains of serotypes A, B and E by acetate, sulfate and calcium.
Mizanur RM; Gorbet J; Swaminathan S; Ahmed SA
Int J Biochem Mol Biol; 2012; 3(3):313-21. PubMed ID: 23097747
[TBL] [Abstract][Full Text] [Related]
19. High Yield Preparation of Functionally Active Catalytic-Translocation Domain Module of Botulinum Neurotoxin Type A That Exhibits Uniquely Different Enzyme Kinetics.
Dhaliwal HK; Thiruvanakarasu N; Kumar R; Patel K; Ambrin G; Cai S; Singh BR
Protein J; 2017 Dec; 36(6):489-501. PubMed ID: 29030733
[TBL] [Abstract][Full Text] [Related]
20. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B.
Swaminathan S; Eswaramoorthy S
Nat Struct Biol; 2000 Aug; 7(8):693-9. PubMed ID: 10932256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
